StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
0075.KL$0.02+0.00%
Fair $0.02+0.0%

0075.KL

LYC Healthcare Berhad

Technology / Information Technology ServicesKuala Lumpur

$0.02

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.02Fund rank 18/100 · Data gapFallback financials|
SA 27/D
F-Score: 5/9
High DebtLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 11%

FCF escenarios

weak_data · normalized FCF $5.0M · quality 13.7/100

Data gap 18/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 18/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

27/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Debt-to-Equity ratio is 5.37, above the 2.0 threshold ROE is -1.1%, below the 5% threshold
Thesis & Journal · 0075.KLLocal privado en este navegador · LYC Healthcare Berhad
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$15M

P/E

N/A

•

EV/EBITDA

4.4x

↓

ROE

-112.1%

↓

Gross Margin

44.3%

↑

Debt/Equity

5.37

↑
52-Week Range$0
$0$0

TradingView lightweight chart

0075.KL price, volumen y niveles de valoración

Último $0.020Periodo -98.4%
Fair value: $0.020

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+34.0%

FCF CAGR

—

FCF margin

14.8%

FCF / Net income

-1.35x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $155.5M · net income $-17.1M · FCF $23.1M

2022-FY → 2025-FY

Gross margin

44.3%-5.5% pts

Operating margin

-0.9%-13.3% pts

Net margin

-11.0%+3.3% pts

FCF margin

14.8%+18.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$155.5M$155.5M$129.0M$92.3M$64.6M
Net Income$-17.1M$-17.1M$-20.8M$-19.2M$-9.2M
EBITDA$20.2M$20.2M$12.1M$8.6M$15.1M
EPS-0.02-0.02-0.03-0.03-0.02
Gross Margin44.3%44.3%52.9%45.1%49.8%
Operating Margin-0.9%-0.9%-5.4%1.7%12.4%
Net Margin-11.0%-11.0%-16.1%-20.8%-14.3%
Balance Sheet
Debt/Equity5.375.372.202.341.42
Current Ratio0.400.40———
Cash Flow
Free Cash Flow$23.1M$23.1M$5.0M$2.5M$-2.5M
Returns
ROE-112.1%-112.1%-59.4%-43.1%-33.5%
Valuation
EV/EBITDA4.374.3715.8024.618.34
P/B0.940.943.683.343.95
Growth & Yield
Revenue Growth20.6%20.6%39.8%42.9%—
EPS Growth24.1%24.1%9.5%-64.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -66.7%

Total return

-66.7%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.03 → -0.02

Residual

-66.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-66.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.